Latest update (checked October 3, 2026): The federal judge overseeing the Ozempic and Wegovy stomach-injury cases (MDL No. 3094), Judge Karen S. Marston, held a five-day expert-evidence hearing from September 14 to 18, 2026. The hearing will help decide which scientific experts can testify about whether these drugs cause the injuries plaintiffs allege. As of our latest check, no ruling has been announced, no settlement program exists, and no trial date has been set. Roughly 4,000 cases are pending, and related motion briefing continues through October 7, 2026.
Last updated: October 2026
Thousands of people who took Ozempic or Wegovy are now suing Novo Nordisk over serious injuries the company allegedly failed to disclose. The novo nordisk lawsuit has become one of the largest pharmaceutical legal battles in the United States, with cases consolidated into a federal multidistrict litigation involving potentially billions of dollars in claims.
If you or someone you love took semaglutide and suffered from gastroparesis, bowel obstruction, or other severe side effects, you may have a legal claim. The cases are moving through federal court in Pennsylvania, and 2026 is shaping up to be a defining year for plaintiffs.
This article covers who qualifies, what the injuries are, how the MDL works, what settlements might look like, and how to protect your right to file before deadlines close.
One fact worth knowing up front: as of early 2026, the MDL had already accumulated thousands of pending cases, making this one of the fastest-growing mass torts in recent pharmaceutical litigation history.
What Is the Novo Nordisk Lawsuit?
The Novo Nordisk lawsuit refers to a growing body of personal injury and product liability claims filed against Novo Nordisk A/S, the Danish pharmaceutical company that manufactures Ozempic and Wegovy. Plaintiffs allege the company sold GLP-1 receptor agonist drugs without adequately warning patients about the risk of severe and potentially permanent gastrointestinal injuries.
The core of every case is the same argument: Novo Nordisk knew or should have known these drugs could cause serious gut damage, and it chose to downplay those risks to protect its market position.
Ozempic was originally approved for type 2 diabetes management. Wegovy was approved for chronic weight management. Both contain semaglutide as the active ingredient. Both are now at the center of major litigation.
| Drug | Approved Use | Active Ingredient |
|---|---|---|
| Ozempic | Type 2 diabetes | Semaglutide |
| Wegovy | Chronic weight management | Semaglutide |
| Rybelsus | Type 2 diabetes (oral) | Semaglutide |
The lawsuits are not class actions in the traditional sense. Most are individual personal injury claims consolidated under a federal MDL. That distinction matters, and we explain it fully later in this article.
Ozempic Lawsuit 2026: Where Things Stand Right Now
The Ozempic lawsuit in 2026 is in an active and critical phase, with bellwether trials scheduled to help determine how juries view the evidence and what damages they are willing to award.
MDL No. 3094 is centralized before Judge Gene E.K. Pratter in the U.S. District Court for the Eastern District of Pennsylvania. As of 2026, the MDL contains several thousand individual cases, with more being added regularly.
The pace of new filings has not slowed. Attorneys expect the case count to climb significantly as more patients connect their diagnoses to their GLP-1 drug use and seek legal representation.
| Metric | Status as of 2026 |
|---|---|
| Court | Eastern District of Pennsylvania |
| MDL Number | MDL No. 3094 |
| Presiding Judge | Judge Gene E.K. Pratter |
| Case Count | Thousands and growing |
| Phase | Discovery and bellwether preparation |
This is not a settled matter. No global settlement has been announced. The litigation is live, contested, and moving toward trial.
Ozempic Lawsuit Update 2026: Latest Court Developments
The most significant 2026 developments in the Ozempic lawsuit involve the selection and scheduling of bellwether trial cases. Bellwether cases are test trials chosen to represent the broader plaintiff pool.
Courts use these trials to see how juries respond to the evidence, the expert witnesses, and the company’s defenses. The outcomes do not bind other plaintiffs, but they heavily influence settlement negotiations.
Novo Nordisk has denied wrongdoing throughout the litigation. The company argues its warning labels were adequate and that the FDA reviewed and approved all labeling decisions.
Plaintiffs counter that internal company documents show Novo Nordisk had data on gastrointestinal risks long before it updated its labels. This “failure to warn” argument is the backbone of nearly every individual claim in the MDL.
Key 2026 legal milestones:
- Expert witness disclosure deadlines in early to mid-2026
- Daubert hearings to challenge or validate expert testimony
- Selection of initial bellwether trial plaintiffs
- Continued case management conferences with Judge Pratter
Key Takeaway: The Ozempic lawsuit is not over. It is moving toward its most important phase, and 2026 decisions will shape whether plaintiffs see settlements or proceed to trial.
Who Qualifies for the Ozempic Lawsuit?
You may qualify for the Ozempic lawsuit if you took Ozempic, Wegovy, or another semaglutide drug and suffered a serious gastrointestinal injury as a documented medical condition. General discomfort or mild nausea alone is unlikely to meet the injury threshold that attorneys are currently accepting.
The qualifying injuries are specific and typically require medical documentation such as hospital records, imaging studies, or a formal diagnosis from a physician.
Most attorneys working on these cases are currently prioritizing claims involving:
- Gastroparesis (stomach paralysis confirmed by gastric emptying study)
- Bowel obstruction (intestinal blockage requiring hospitalization or surgery)
- Intestinal ileus (functional bowel obstruction without mechanical cause)
- Severe cyclic vomiting requiring emergency care or hospitalization
| Qualifying Factor | Detail |
|---|---|
| Drug Used | Ozempic, Wegovy, Rybelsus, or similar semaglutide product |
| Injury Type | Gastroparesis, bowel obstruction, ileus, or severe GI complication |
| Medical Documentation | Hospital records, imaging, or physician diagnosis required |
| Injury Timing | Side effects occurring during or shortly after semaglutide use |
If you are unsure whether your situation qualifies, a case evaluation by a mass tort attorney is the most direct way to find out.
Ozempic Lawsuit Eligibility Requirements Explained
Eligibility for the Ozempic lawsuit is determined by three main factors: the drug you took, the injury you suffered, and when it happened. All three need to align for a claim to move forward.
First, you must have taken a GLP-1 drug manufactured or sold by Novo Nordisk. Eli Lilly makes Mounjaro and Zepbound, which are related but separate cases.
Second, the injury must be documented. Attorneys need medical records showing you received a diagnosis consistent with the injuries at issue in the MDL. Self-reported symptoms without clinical documentation are generally not sufficient.
Third, the timing matters. You generally need to show that your injury occurred while you were using the drug or within a reasonable medical timeframe after stopping use.
Eligibility checklist:
- You used Ozempic, Wegovy, or Rybelsus
- You were diagnosed with gastroparesis, bowel obstruction, or a related severe GI condition
- You have medical records confirming that diagnosis
- Your diagnosis occurred during or after your use of the drug
- You have not already settled a claim for the same injury
Key Takeaway: Three things determine eligibility: the drug taken, the injury diagnosed, and the medical documentation supporting both.
Gastroparesis Lawsuit: Can Ozempic Cause Stomach Paralysis?
Gastroparesis is a condition where the stomach cannot empty itself properly because the muscles controlling gastric movement are damaged or impaired. Scientific studies and FDA-reviewed data have linked semaglutide to delayed gastric emptying, which is the mechanism behind gastroparesis.
The condition causes intense nausea, vomiting, bloating, and in severe cases, malnutrition and hospitalization. For some patients, the damage appears to be long-lasting even after stopping the drug.
Plaintiffs in the gastroparesis track of the Ozempic lawsuit argue that Novo Nordisk knew delayed gastric emptying was a pharmacological effect of semaglutide but did not adequately communicate that this effect could cause permanent or near-permanent gastroparesis in some patients.
A 2022 peer-reviewed study published in JAMA found that GLP-1 receptor agonist users faced a significantly higher risk of gastroparesis compared to people using other diabetes medications. That study became a key reference in plaintiff legal filings.
| Gastroparesis Claim Details | Information |
|---|---|
| Mechanism | Delayed gastric emptying caused by semaglutide |
| Symptoms | Nausea, vomiting, bloating, early satiety, weight loss |
| Diagnosis Required | Gastric emptying study (nuclear medicine scan) |
| Estimated Claim Strength | High; well-supported by medical literature |
Ozempic Bowel Obstruction Lawsuit: What Plaintiffs Are Claiming
Bowel obstruction claims argue that Ozempic caused blockages in the small or large intestine, requiring emergency care, hospitalization, and sometimes surgery. This is a distinct injury category from gastroparesis and involves different physical mechanisms.
Plaintiffs in this track allege that semaglutide’s effect on gut motility can slow intestinal movement to the point of creating a functional or physical obstruction. When food and waste cannot move through the bowel, the consequences can be life-threatening.
Several plaintiffs have reported undergoing surgery to remove sections of bowel damaged by prolonged obstruction. Others describe extended hospitalizations, feeding tube placement, and permanent changes to their digestive function.
What bowel obstruction plaintiffs are claiming:
- Novo Nordisk failed to warn that the drug could cause intestinal blockages
- The company had data suggesting elevated GI obstruction risk before lawsuits were filed
- Plaintiffs suffered preventable injuries because warnings were inadequate
- They deserve compensation for medical costs, lost income, and pain and suffering
The bowel obstruction claims tend to involve more severe documented injuries, which typically correlates with higher potential compensation in settlement negotiations.
Ozempic Stomach Paralysis Lawsuit: How Severe Is the Injury?
Stomach paralysis in the Ozempic lawsuit context refers to severe gastroparesis where the stomach has essentially stopped functioning at a normal level. It is the most serious form of the gastric emptying claims and the one that tends to attract the highest potential case values.
Some plaintiffs report being unable to eat solid food for months. Others have required feeding tubes. A portion of those diagnosed say their condition persisted and worsened even after stopping Ozempic or Wegovy entirely.
Think of it like this: if your car engine runs too slow because of a calibration problem, you can slow the car. But if the engine seizes completely, the car stops. That is what severe gastroparesis does to digestion.
| Severity Level | Symptoms | Typical Medical Intervention |
|---|---|---|
| Mild | Nausea, bloating, occasional vomiting | Dietary changes, medication |
| Moderate | Frequent vomiting, significant weight loss | IV fluids, anti-nausea medication, monitoring |
| Severe | Inability to eat, malnutrition, hospitalization | Feeding tube, extended hospital stay, possible surgery |
Severe cases with hospitalization, permanent dietary restrictions, or long-term medical care are the ones attorneys prioritize for the highest compensation tiers.
Key Takeaway: Stomach paralysis severity directly affects how much a claim may be worth, with severe and documented cases carrying the highest potential value in the MDL settlement structure.
Ozempic Suicidal Ideation Lawsuit: What the FDA Said
The suicidal ideation claims represent a separate track within the broader Novo Nordisk litigation. These plaintiffs allege that semaglutide drugs triggered thoughts of self-harm or suicidal ideation that were not disclosed as a potential risk.
In 2023, the FDA announced it was investigating reports of suicidal thoughts associated with GLP-1 receptor agonist drugs, including semaglutide. The agency was reviewing reports submitted through its adverse event reporting system.
The FDA ultimately concluded in late 2023 that its review of available data did not establish a causal link between GLP-1 drugs and suicidal ideation at the population level. However, that finding did not end the lawsuits. Plaintiffs argue the FDA’s review was based on limited data and that individual causation is still a viable legal argument in court.
What suicidal ideation plaintiffs allege:
- Novo Nordisk should have investigated and disclosed the psychiatric risk earlier
- Some patients experienced rapid personality or mood changes after starting semaglutide
- The company relied on incomplete adverse event data in its safety assessments
- Individual plaintiffs can still show personal causation even without population-level proof
These cases are considered higher risk for plaintiffs than the GI injury claims because the FDA did not confirm the causal link. But they are still active in litigation.
Novo Nordisk Failure to Warn: The Core Legal Argument
The failure to warn claim is the single most important legal theory across all Novo Nordisk lawsuits. Every plaintiff, regardless of their specific injury, is relying on some version of this argument.
Product liability law in the United States holds drug manufacturers to a duty to provide adequate warnings about known or reasonably knowable risks. When a company knows a drug carries a serious risk and buries that information in fine print or omits it entirely, it can be held liable for resulting injuries.
Plaintiffs argue that Novo Nordisk had internal data showing elevated GI risks well before it updated its warning labels. They say the company prioritized sales over safety disclosures.
Novo Nordisk’s defense is that the FDA approved its labeling. This is the “federal preemption” defense, which argues that because the FDA signed off on the label, state tort claims cannot hold the company liable for inadequate warnings.
Courts have generally not accepted blanket preemption arguments in pharmaceutical failure-to-warn cases. The Supreme Court’s ruling in Wyeth v. Levine (2009) established that drug companies can update their own labels unilaterally to add warnings, which means federal approval does not shield them from state failure-to-warn claims.
That 2009 precedent is working in plaintiffs’ favor here.
What Is the Novo Nordisk MDL and How Does It Work?
The Novo Nordisk MDL refers to Multidistrict Litigation No. 3094, a federal legal proceeding that consolidates hundreds or thousands of similar lawsuits into one court for pretrial purposes. It is not a class action. Each plaintiff’s case remains individual.
MDL works like a sorting system for mass litigation. Instead of hundreds of courts across the country each managing their own discovery processes, deposing the same Novo Nordisk executives, and hiring the same expert witnesses, all that pretrial work happens once before a single judge.
The efficiency is enormous. So is the leverage it creates for settlement negotiations.
| Feature | Class Action | MDL (Multidistrict Litigation) |
|---|---|---|
| Individual claims? | No; one shared claim | Yes; each plaintiff keeps their own case |
| Settlement payout | Divided equally | Varies by injury severity |
| Trial? | Rarely; usually settles | Bellwether trials guide settlement |
| Who controls? | Lead counsel / judge | Plaintiffs’ steering committee |
In an MDL, a plaintiffs’ steering committee coordinates strategy for all cases. Individual attorneys still represent their own clients. But the big pretrial battles are fought collectively.
Key Takeaway: The Novo Nordisk MDL is not a class action. Individual plaintiffs keep their own cases and their own potential compensation amounts.
Ozempic MDL Bellwether Trials: Why They Matter for Your Claim
Bellwether trials are test cases selected from the MDL pool to go to trial first. They are chosen to represent the range of facts, injuries, and circumstances across all the plaintiffs.
When a jury hears a bellwether case and delivers a verdict, that verdict does not automatically apply to anyone else. But it sends a loud signal. If a jury awards $20 million to a gastroparesis plaintiff, Novo Nordisk’s legal team knows what is possible. That shifts the settlement math dramatically.
The bellwether process in MDL No. 3094 is one of the most closely watched events in pharmaceutical litigation for 2026. Several trial dates are anticipated.
If early bellwether verdicts favor plaintiffs, the pressure on Novo Nordisk to reach a global settlement will increase sharply. If early verdicts favor the company, settlement numbers may drop or the litigation may thin out.
What bellwether outcomes typically trigger:
- Strong plaintiff verdict: Company enters settlement negotiations more seriously
- Verdict for the company: Some plaintiffs may withdraw weaker claims
- Mixed outcome: Negotiations become more nuanced and injury-tier-based
- Settlement mid-trial: Can trigger broader global settlement talks
This is why your claim’s position in the MDL matters. Being prepared with strong documentation now gives your claim the best standing when settlement talks begin.
How to File an Ozempic Lawsuit in 2026
Filing an Ozempic lawsuit in 2026 starts with a case evaluation, not a courthouse. Individual plaintiffs do not file directly into the MDL on their own.
Here is how the process actually works for most people:
Step 1: Gather your medical records.
You need documentation of your drug use and your diagnosis. This includes pharmacy records showing you were prescribed Ozempic or Wegovy, and hospital or physician records showing your GI injury diagnosis.
Step 2: Contact a mass tort attorney.
Look for firms that specifically handle pharmaceutical mass torts. They will do a free initial case review. They will tell you if your injuries and records meet the threshold they are filing cases on.
Step 3: Sign a representation agreement.
If your case qualifies, you sign a contingency fee agreement. That means you pay nothing unless you recover compensation. Attorney fees typically come as a percentage of any settlement or award.
Step 4: Your attorney files your case.
The attorney files your complaint, which gets transferred into MDL No. 3094 in Pennsylvania. Your case joins thousands of others in the pretrial coordination.
Step 5: Participate in the process.
You may be asked to answer written questions (interrogatories), provide more records, or give a deposition. Your attorney guides all of this.
| Filing Step | What Happens |
|---|---|
| Case evaluation | Attorney reviews your records for free |
| Representation agreement | You sign; no upfront cost |
| Complaint filed | Case transferred to MDL in Pennsylvania |
| Discovery phase | Records shared, depositions taken |
| Settlement or trial | Resolution reached with compensation |
Ozempic Lawsuit Statute of Limitations: Don’t Miss Your Window
The statute of limitations for an Ozempic lawsuit is the legal deadline by which you must file your claim. Miss it, and you permanently lose your right to seek compensation, no matter how serious your injury.
Most states apply a two-year statute of limitations for personal injury claims. The clock typically starts from the date you knew or reasonably should have known that your injury was connected to the drug.
This “discovery rule” is critical. If you were diagnosed with gastroparesis in 2022 but did not learn until 2024 that Ozempic may have caused it, many states would start your clock in 2024.
| State | Typical Statute of Limitations | Notes |
|---|---|---|
| California | 2 years | Discovery rule applies |
| Florida | 2 years | Changed from 4 years in 2023 |
| New York | 3 years | Discovery rule applies |
| Texas | 2 years | Strict application |
| Pennsylvania | 2 years | MDL home state |
Every state is different. Some have tolling rules that pause the clock in certain circumstances. Do not assume your window is still open without checking.
The safest move in 2026: Do not wait. The longer you wait, the greater the risk that your deadline passes.
Key Takeaway: The statute of limitations is a hard stop. Waiting to file in hopes of better settlement offers is a gamble that can cost you your entire claim.
Novo Nordisk Settlement 2026: Is a Deal Coming?
No global Novo Nordisk settlement has been announced as of 2026, but the conditions for one are building steadily. The bellwether trial schedule, rising case counts, and the strength of the medical literature supporting plaintiff claims all point toward eventual resolution.
Major pharmaceutical mass torts typically settle before or shortly after early bellwether trials. The pattern has repeated across talcum powder litigation, opioid cases, and 3M earplugs.
Novo Nordisk is a financially strong company. It has the resources to fight this litigation for years. But it also has strong business incentives to resolve cases and protect its brand reputation around Ozempic and Wegovy, which remain among the most commercially successful drugs in the world.
Factors pushing toward settlement:
- Growing MDL case count creates compounding litigation costs
- Strong medical literature supporting gastric emptying risk
- Bellwether trial outcomes could trigger large jury awards
- Company interest in protecting ongoing drug revenue
Factors that could delay settlement:
- Company’s federal preemption defense argument
- Ongoing FDA review and regulatory complexity
- Mixed results expected in early bellwether trials
Analysts familiar with pharmaceutical mass torts suggest a structured global settlement is more likely than a string of individual trials, but the timing remains uncertain.
Ozempic Lawsuit Settlement Amount: What Could Plaintiffs Receive?
No official settlement amounts have been set in the Novo Nordisk MDL because no global settlement has been reached yet. However, attorneys and legal analysts have offered ranges based on comparable mass tort outcomes and injury severity.
Settlement amounts in pharmaceutical mass torts typically vary based on a tiered system. More severe injuries with stronger documentation receive higher compensation.
| Injury Tier | Description | Estimated Range |
|---|---|---|
| Tier 1 | Mild GI symptoms, no hospitalization | $10,000 to $50,000 |
| Tier 2 | Diagnosed gastroparesis, hospitalization | $75,000 to $250,000 |
| Tier 3 | Severe gastroparesis, surgery, feeding tube | $250,000 to $1,000,000+ |
| Tier 4 | Permanent disability, wrongful death | Case-specific, potentially higher |
These are estimates based on comparable litigation history. They are not guarantees and are not official figures from the court or any party.
Factors that affect individual settlement value:
- Severity and permanence of the injury
- Medical costs incurred (past and future)
- Lost wages or earning capacity
- Age and life expectancy of the plaintiff
- Strength of the medical documentation
- Whether punitive damages become a factor in any trial
How Much Can I Get From the Ozempic Lawsuit?
The amount you personally can get from the Ozempic lawsuit depends entirely on your specific injury, your medical documentation, and where the settlement process ends up. There is no flat payout for everyone.
Plaintiffs with the most serious injuries, clear medical records, and strong causation evidence stand to receive the most. People with mild or undocumented symptoms are less likely to see large awards.
To put it in plain terms: this is not a lottery ticket situation. The compensation is meant to reflect what the injury actually cost you, physically, financially, and in quality of life.
What drives your individual compensation up:
- Longer hospital stays or multiple hospitalizations
- Surgical procedures required because of the injury
- Permanent dietary restrictions or ongoing medical treatment
- Job loss or reduced ability to work
- Young age at time of injury (longer projected impact)
What can reduce your compensation:
- Pre-existing GI conditions that complicate causation
- Failure to seek medical care and documentation
- Delayed filing or weak documentation of drug use
- No confirmed clinical diagnosis of a qualifying injury
Realistic expectations matter. Attorneys will give you a clearer picture of where your case falls during your case evaluation.
Novo Nordisk Class Action vs. Personal Injury Lawsuit: What’s the Difference?
The Novo Nordisk litigation is structured as individual personal injury claims within an MDL, not as a traditional class action. Understanding the difference is important because it directly affects how much money you can receive.
In a class action, all plaintiffs share one lawsuit and divide the settlement equally, regardless of how badly any individual was hurt. That is why class action payouts can be as low as a few dollars per person.
In a personal injury MDL, every plaintiff has their own separate case with their own compensation amount. If your injury was severe and your neighbor’s was mild, you do not split the pot equally. Your damages are calculated individually.
| Feature | Class Action | Personal Injury MDL |
|---|---|---|
| Shared lawsuit | Yes | No; each case is separate |
| Equal payouts | Usually | No; based on individual injury |
| One attorney for all | Often | Individual attorneys per client |
| Control over your case | Minimal | Retained |
| Best for | Consumer fraud, small losses | Serious physical injury |
The Novo Nordisk MDL structure is better for people with serious documented injuries because your compensation reflects the actual harm done to you specifically.
This also means that doing nothing and waiting to join a class action that may award you $50 is not a real strategy here. The personal injury track is where significant compensation lives.
Key Takeaway: The Novo Nordisk litigation is personal injury MDL, not a class action. Your compensation reflects your specific injury, not a shared pool divided among thousands.
Frequently Asked Questions
Is there an active Novo Nordisk lawsuit in 2026?
Yes, the Novo Nordisk lawsuit is active in 2026.
Cases are consolidated in MDL No. 3094 before a federal judge in Pennsylvania, with bellwether trials anticipated during the year.
The litigation covers injuries from Ozempic, Wegovy, and other semaglutide drugs.
Who qualifies to file an Ozempic lawsuit?
You may qualify if you took Ozempic or Wegovy and were diagnosed with gastroparesis, bowel obstruction, or a related serious GI condition.
Medical documentation of both drug use and injury is required.
Attorneys are currently prioritizing cases with confirmed diagnoses and hospital records.
How much money can I get from the Novo Nordisk lawsuit?
No official settlement amounts exist yet, but estimates based on comparable mass torts range from $10,000 for mild cases to over $1 million for severe, permanent injuries.
Your specific amount depends on injury severity, medical costs, and documentation strength.
Payouts are individual, not shared equally among all plaintiffs.
What injuries are linked to the Ozempic and Wegovy lawsuit?
The primary injuries are gastroparesis (stomach paralysis), bowel obstruction, intestinal ileus, and severe cyclic vomiting requiring hospitalization.
Suicidal ideation claims exist in a separate track but face a higher legal bar due to FDA findings.
GI injury claims with medical documentation are currently the strongest cases in the MDL.
What is the deadline to file an Ozempic lawsuit claim?
Most states have a two-year statute of limitations for personal injury claims, starting from when you knew or should have known your injury was connected to the drug.
Deadlines vary by state, and some states apply strict rules with no tolling provisions.
The safest approach is to file or consult an attorney as soon as possible in 2026.
Where This Lawsuit Stands and What to Do Now
The Novo Nordisk lawsuit is one of the most significant pharmaceutical cases moving through U.S. courts right now. Thousands of people who trusted a drug to help them manage diabetes or weight loss ended up facing serious, sometimes permanent, injuries they were never warned about.
If you took Ozempic or Wegovy and experienced severe GI problems, your window to act is open but not unlimited. The MDL is growing, bellwether trials are approaching, and your claim’s value depends on acting while your records are current and your filing deadline has not expired.
Get your medical records together. Talk to a mass tort attorney who handles pharmaceutical cases. Find out where your claim stands before 2026 closes a door you cannot reopen.
